x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012794
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IHC, IF, Flow Cyt |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human RHAMM/CD168 protein. The antigenic peptide spans a region that is 100% conserved among the four isoforms of RHAMM/CD168 reported in , iprot. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | HMMR |
| UniProt No. | O75330 |
| Gene ID | 3161 |
| Gene Description | Receptor for Hyaluronic acid-Mediated Motility was first identified as a putative receptor for hyaluronic acid that modulated HA-mediated cell motility. RHAMM/CD168 is functionally similar to the HA receptor CD44; however in contrast to CD44, RHAMM/CD168 does not contain a transmembrane domain or a signal peptide leader sequence, and so is not targeted exclusively to the cell membrane. RHAMM/CD168 has multiple isoforms; some are reportedly exported to the cell membrane in response to signaling by growth factors and cytokines, whereas others have been implicated in intracellular functions including mitotic spindle regulation. Cell surface RHAMM/CD168 is localized to membrane ruffles, consistent with proteins that regulate cell motility. Numerous research studies have reported that the expression of RHAMM/CD168 is positively associated with cancer cell growth, motility and/or metastasis, in addition to HA-mediated inflammation, suggesting the potential for therapeutic approaches that target HA-receptor mediated signaling. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
